Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN4A | P35499 | 2/20 | 0.48 |
| ▸ | DPP4 | P27487 | 2/20 | 0.48 |
| ▸ | F2 | P00734 | 1/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.38 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28458580 | 0.98 | SCN4A (0.47) | SCN4ADPP4F2SLC6A4LTA4H | |
| SCHEMBL11462370 | 0.85 | DPP4 (0.39) | SCN4ADPP4F2SLC6A4ADRA2A | |
| SCHEMBL27458766 | 0.85 | SCN4A (0.37) | SCN4ADPP4F2SLC6A4LTA4H | |
| SCHEMBL9274678 | 0.85 | SLC6A9 (0.43) | DPP4F2TSHR | |
| SCHEMBL4671890 | 0.80 | CFTR (0.48) | SLC6A4 | |
| SCHEMBL9861253 | 0.80 | HTT (0.46) | TSHR | |
| SCHEMBL15345403 | 0.79 | SLC6A2 (0.51) | SLC6A4HTR2A | |
| SCHEMBL28144445 | 0.78 | ADRA2A (0.42) | SCN4ADPP4F2ADRA2AADRA2C | |
| SCHEMBL8808480 | 0.78 | SCN4A (0.35) | SCN4ADPP4F2SLC6A4LTA4H | |
| SCHEMBL29270324 | 0.76 | LTA4H (0.45) | SCN4ADPP4F2LTA4HTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113024389-B | Preparation method of substituted phenoxybenzylamine compound and pyrazole carboxamide compound | 山东海利尔化工有限公司 | 2021-08-31 | — | — | CN | claimed |
| CN-113164451-A | Methods and compositions for treating glaucoma and related disorders | 奥库菲尔制药股份有限公司 | 2021-07-23 | — | — | CN | claimed |
| CN-113164452-A | Methods and compositions for treating presbyopia, mydriasis and other ocular disorders | 奥库菲尔制药股份有限公司 | 2021-07-23 | — | — | CN | claimed |
| CN-113024389-A | Preparation method of substituted phenoxybenzylamine compound and pyrazole carboxamide compound | 山东海利尔化工有限公司 | 2021-06-25 | — | — | CN | claimed |
| CN-1374861-A | Methods for modulating the human sexual response | ZONAGEN INC (US) | 2002-10-16 | — | — | CN | claimed |
| CN-117750948-A | Compositions and methods for targeted systemic delivery to cells | 瑞科德治疗公司 | 2024-03-22 | — | — | CN | disclosed |
| CN-117597327-A | Pharmaceutical preparation | 第一波动生物制药股份有限公司 | 2024-02-23 | — | — | CN | disclosed |
| EP-3131877-B1 | BIGUANIDE COMPOUNDS | IMMUNOMET THERAPEUTICS INC (US) | 2023-07-19 | — | — | EP | disclosed |
| CN-110831584-B | Targeted drug rescue with novel compositions, combinations and methods thereof | 埃克塞瓦有限责任公司 | 2023-03-10 | — | — | CN | disclosed |
| CN-115216438-A | Preparation method and application of engineering myocardial tissue based on big blue flashing butterfly wing | 苏州大学 | 2022-10-21 | — | — | CN | disclosed |
| US-11465989-B2 | Guanidine compounds and use thereof | ImmunoMet Therapeutics, Inc. (US) | 2022-10-11 | — | — | US | disclosed |
| CN-115120405-A | Delivery device for bioabsorbable ocular drugs | 多斯医学公司 | 2022-09-30 | — | — | CN | disclosed |
| US-6610747-B2 | Such as 4-(2,3-dihydro-1-benzothien-5-yloxy)-3-((methylamino) methyl)-benzenesulfonamide for use as serotonin re-uptake inhibitors (SSRIs) in treatment of depression, attention deficit hyperactivity disorder, obsessive-compulsive disorder | PFIZER INC. | 2003-08-26 | — | — | US | disclosed |
| WO-2003064376-A1 | SUBSTITUTED METHYLENE AMIDE DERIVATIVES AS MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPS) | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2003-08-07 | — | — | WO | disclosed |
| US-20030060456-A1 | Such as 4-(2,3-dihydro-1-benzothien-5-yloxy)-3-((methylamino) methyl)-benzenesulfonamide for use as serotonin re-uptake inhibitors (SSRIs) in treatment of depression, attention deficit hyperactivity disorder, obsessive-compulsive disorder | PFIZER INC. | 2003-03-27 | — | — | US | disclosed |
| CN-1374861-A | Methods for modulating the human sexual response | ZONAGEN INC (US) | 2002-10-16 | — | — | CN | disclosed |
| CN-1368499-A | Dihydropyridine derivatives having guaiazoxypropanolamine and phenoxypropanolamine structures | CHEN YINGJUN (CN) | 2002-09-11 | — | — | CN | disclosed |
| CN-1309561-A | Therapeutic agent for erectile dysfunction | MOCHIDA PHARM CO LTD (JP) | 2001-08-22 | — | — | CN | disclosed |
| CN-1207733-A | Novel piperazinylalkylthiophrimidine derivs., pharmaceutical compositions contg. same and process for preparation of such compounds | EGYT GYOGYSZERVEGYESZETI GYAR (HU) | 1999-02-10 | — | — | CN | disclosed |
| EP-0049577-A1 | Alpha-cyanophenoxybenzylamine derivatives, processes for preparing them, and their use as intermediates for the preparation of pyrethroid insecticides | ICI AUSTRALIA LIMITED (AU) | 1982-04-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030060456-A1 | Such as 4-(2,3-dihydro-1-benzothien-5-yloxy)-3-((methylamino) methyl)-benzenesulfonamide for use as serotonin re-uptake inhibitors (SSRIs) in treatment of depression, attention deficit hyperactivity disorder, obsessive-compulsive disorder | HTR6, HTR2C, SLC6A3 | SCN4A 1207/4885DPP4 4142/4885F2 4429/4885 |
| US-11465989-B2 | Guanidine compounds and use thereof | PC, TFAM, PCK2 | SCN4A 3804/4885DPP4 2503/4885F2 4805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.